The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: First, on the IL-2, is there any potential antitumor benefit lost or left on the table by not targeting the IL-2 receptor alpha, beta gamma? And how
do you think about the risk or balance between safety and efficacy as it relates to alpha subunit?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. And then sticking with the IL-2 for my follow-up. You talked about trying to kind of rapidly dose escalate to get to relevant doses. Can
you elaborate a little bit on how long you think it will take to get to effective doses? If you think you can start at a dose level that could be close to
efficacious or if you're going to need to start pretty low and making it take some time to get to efficacy?
Stina Singel
That's a great question. We are not the first program to put an IL-2 molecule in the market to try to give it in outpatient setting. What we can learn
from other programs in addition to what we understand about our molecule, we are intending to start at an efficacious dose. What I mean by
quickly escalating is that we know a lot of the side effects are very acute, meaning that within the dose-limiting toxicity, evaluation window of 21
days, we should be able to see it. So essentially, every about 2 months or so, we should be able to dose escalate. And as I mentioned, we intend to
start at a dose that is already efficacious based on what we understand from other programs in addition to our own data about our molecule in
the nonhuman primate studies.
Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst
: I was just hoping you could expand a bit on what you chose TLR7/8? And also, if there's a theoretical advantage of activating the plasmacytoid DCs
versus just conventional DCs. And also, is there any theoretical advantage, I guess, of an intratumoral approach versus some of the ligand linked
approaches for TLR7/8?
Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst
: And if I could just do a follow-up, what our, I guess, the initial indication -- or the initial combinations that you would think would make the most
sense for HPV-associated tumors. And what will you be looking at for those initial combination with TransCon TLR7/8?
Stina Singel
Yes. So in the HPV associated tumor types, such as head and neck cancer and cervical cancer, we know that checkpoint inhibitor, pembrolizumab,
particularly, is part of standard of care. So with TLR7/8 Agonist, we are planning to add to what is standard of care as an additive agent to make
checkpoint inhibitors work even better.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
|
